<DOC>
	<DOC>NCT00931957</DOC>
	<brief_summary>The purpose of this study is to find if Etanercept can improve the outcome of ocular lesions of Behcet's Disease treated with Methotrexate and Prednisolone</brief_summary>
	<brief_title>Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease</brief_title>
	<detailed_description>To test in a randomized single blind control trial the efficacy of Etanercept in patients with posterior uveitis and/or retinal vasculitis of Behcet's disease treated with Methotrexate and prednisolone</detailed_description>
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Uveal Diseases</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Behcet's Disease according to the International Criteria for Behcet's disease (ICBD) Active posterior uveitis and/or retinal vasculitis Visual acuity inferior to 1/10 on Snellen chart Being under cytotoxic drugs or having received them in the past 2 months Not being able to follow the one year treatment and the regular follow ups</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Etanercept</keyword>
	<keyword>Behcet's syndrome</keyword>
	<keyword>Behcet's Disease</keyword>
	<keyword>Ocular Lesions</keyword>
	<keyword>Uveitis</keyword>
	<keyword>Retinal Vasculitis</keyword>
</DOC>